Zacks Small Cap Lowers Earnings Estimates for Longeveron

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at Zacks Small Cap decreased their FY2025 earnings per share estimates for shares of Longeveron in a report issued on Monday, March 3rd. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($1.84) for the year, down from their previous forecast of ($1.28). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

LGVN has been the topic of several other research reports. Roth Mkm assumed coverage on shares of Longeveron in a research report on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Roth Capital raised shares of Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Longeveron in a report on Monday.

Longeveron Price Performance

NASDAQ LGVN opened at $1.40 on Wednesday. The business’s fifty day moving average is $1.64 and its 200-day moving average is $1.89. The stock has a market capitalization of $20.77 million, a price-to-earnings ratio of -0.22 and a beta of 0.36. Longeveron has a one year low of $0.77 and a one year high of $6.40.

Hedge Funds Weigh In On Longeveron

Several large investors have recently modified their holdings of LGVN. State Street Corp purchased a new stake in shares of Longeveron during the 3rd quarter valued at approximately $29,000. Northern Trust Corp bought a new stake in Longeveron during the 4th quarter valued at $31,000. Jane Street Group LLC purchased a new stake in shares of Longeveron during the fourth quarter worth $35,000. Virtu Financial LLC bought a new position in shares of Longeveron in the fourth quarter worth $53,000. Finally, Geode Capital Management LLC grew its position in shares of Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares in the last quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.